Latest Articles

Publication Date
Selective targeting of genes regulated by zinc finger proteins in endometriosis and endometrioid adenocarcinoma by zinc niflumato complex with neocuproine - Nature.com

Selective targeting of genes regulated by zinc finger proteins in endometriosis and endometrioid adenocarcinoma by zinc niflumato complex with neocuproine Nature.com

Published: March 24, 2025, 4:17 p.m.
The association of molecular classification with fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma:A retrospective study - Frontiers

The association of molecular classification with fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma:A retrospective study Frontiers

Published: March 24, 2025, 4:03 p.m.
Selective targeting of genes regulated by zinc finger proteins in endometriosis and endometrioid adenocarcinoma by zinc niflumato complex with neocuproine.

Inadequate angiogenesis of endometriotic implants stimulated by the inflammatory microenvironment in the uterine region leads to the development of gynecological diseases, which significantly reduce the fertility and vitality of young …

Published: March 24, 2025, midnight
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Finance

Published: March 19, 2025, 11 a.m.
Atypical Endometriosis - An Overview of the Issue and Personal Experiences.

Endometriosis is a chronic, estrogen-dependent, inflammatory disease characterized by the growth of endometriotic tissue outside the uterus. Among the wide spectrum of clinical manifestations of endometriosis, chronic pelvic pain, dysmenorrhea, …

Published: March 17, 2025, 12:08 a.m.
Fallopian fimbriae entrapped in an ovarian endometriotic cyst mimicking malignancy: a case report.

Ovarian endometriotic cysts are associated with an increased risk of clear cell and endometrioid carcinomas, as well as borderline neoplasms. Although contrast-enhancing nodules on magnetic resonance imaging (MRI) suggest malignancy, …

Published: March 17, 2025, midnight
FIGURE 1 MTFR2 is highly expressed in endometrial carcinoma and is a... - ResearchGate

FIGURE 1 MTFR2 is highly expressed in endometrial carcinoma and is a... ResearchGate

Published: March 14, 2025, 10:44 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!